Table 5.
Distribution of ICHD3 diagnoses with different mitochondrial phenotypes.
| Phenotype | No | MO | MA/HM | CM | pMO | iETTH | fETTH | Others | Tot |
|---|---|---|---|---|---|---|---|---|---|
| ADOA | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| CPEO | 1 | 0 | 0 | 0 | 2 | 2 | 0 | 0 | 5 |
| CPEO plus | 9 | 9 | 0 | 1 | 4 | 1 | 0 | 1 | 25 |
| KSS | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| MELAS | 0 | 3 | 1 | 0 | 0 | 0 | 1 | 1 | 6 |
| MICU1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| MM | 0 | 3 | 0 | 0 | 1 | 1 | 0 | 0 | 5 |
| Tot | 10 | 18 | 2 | 1 | 7 | 4 | 2 | 2 | 46 |
No no headache, MO migraine without aura, MA migraine with aura, HM hemiplegic migraine, CM chronic migraine, pMO probable migraine without aura, iETTH infrequent tension-type headache, fETTH frequent tension-type headache. ADOA autosomal dominant optic atrophy, CPEO chronic progressive external ophthalmoplegia, KSS Kearns-Sayre syndrome, MELAS mitochondrial encephalopathy, lactic acidosis and stroke-like episodes, MICU1 mitochondrial calcium uptake 1, MM other mitochondrial myopathy.